Phase III CheckMate-73L trial did not meet its primary endpoint in stage III non-small cell lung cancer – BMS
Bristol Myers Squibb announced the Phase III CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell… read more.
